Dermapharm Reports Q3 2026 Financial Results and Confirms Annual Guidance

For the first nine months of 2026, Dermapharm reported revenue of 884 million euros, representing a 2% increase compared to the previous year, driven by demand for branded pharmaceuticals and recent acquisitions. The company's adjusted EBITDA rose by 5% to 248 million euros, with the corresponding margin improving from 27.1% to 28%. Despite these operational gains, net profit declined by nearly 2 million euros to 93.3 million euros due to a weaker financial result. CEO Hans-Georg Feldmeier confirmed the company's full-year 2026 guidance, targeting revenue between 1.182 billion and 1.218 billion euros and an adjusted operating result between 331 million and 341 million euros.